About
Neuronix develops methods for modifying the course of treatment for Alzheimer's disease, offering the potential for long-term improvement in patient quality of life. The neuroAD system is based on the company's core noninvasive cortical enhancer technology and is CE marked for the treatment of mild to moderate Alzheimer's disease. The company's patented technology uses magnetic stimulation interlaced with cognitive training and directed at specific brain regions affected by Alzheimer's disease. This combination induces long-term potentiation, which is associated with learning and memory processes. Several published studies performed at the Beth Israel Deaconess Medical Center (Harvard Medical School, Massachusetts), in Israel, and in other locations showed statistically significant clinical results compared with placebo following six weeks of daily one-hour sessions. The neuroAD therapy system is CE marked for commercial use in Europe for the treatment of Alzheimer's disease. A multi-center clinical study was recently completed in the United States and will be used to support a submission seeking US FDA clearance. Neuronix is a privately held company with headquarters in Israel and subsidiaries in the United States and United Kingdom.
Funding history · 3 rounds · $17.5M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the primary focus of Neuronix's technology?
- Neuronix develops methods for modifying the course of treatment for Alzheimer's disease, utilizing magnetic stimulation technology.
- What is the status of Neuronix as of April 2020?
- According to startupim data, Neuronix became inactive in April 2020 and ceased to operate.
- What is the name of Neuronix's core product for Alzheimer's treatment?
- Neuronix's core product is the neuroAD system, which is based on noninvasive cortical enhancer technology.
- Has Neuronix's neuroAD system received regulatory approval in Europe?
- Yes, the neuroAD therapy system is CE marked for commercial use in Europe for the treatment of mild to moderate Alzheimer's disease.
- What was the outcome of the FDA Advisory Panel's review of Neuronix's neuroAD in March 2019?
- In March 2019, an FDA Advisory Panel rejected Neuronix's neuroAD for Alzheimer's Disease.
- When did Neuronix report positive results from its multi-center Alzheimer's study?
- Neuronix reported positive results from its multi-center Alzheimer's study at the Clinical Trials in Alzheimer's Disease (CTAD) conference in January 2017.
- What was Neuronix's total funding raised in USD?
- Neuronix raised a total of $17,500,000 USD across multiple undisclosed rounds. For full financing history, please refer to startupim.
- When was Neuronix founded and where is its headquarters located?
- Neuronix was founded in January 2008 and is headquartered in Yokne'am Illit, Israel.